LXRX Stock Analysis: Buy, Sell, or Hold?
LXRX - Lexicon Pharmaceuticals, Inc.
$1.56
0.05 (3.31%)
▲
5d:
-9.3%
30d:
+0.0%
90d:
+33.33%
HOLD
LOW Confidence
Analysis Updated: Mar 31, 2026 12:00 AM ET
Earnings: May 12, 2026
Smart Money Accumulation
LXRX is down 9.3% this week, but smart money is accumulating calls. Top strike: $1.5 2026-04-17 with 2,486 OI. Call ratio: 96% View Scanner →
Strength: 9.2/10
Get Alerted When LXRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LXRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LXRX shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LXRX is currently trading at $1.56, which is considered slightly low relative to its 30-day fair value range of $1.52 to $1.68.
Technical Outlook: Technically, LXRX is in a strong uptrend. Immediate support is located at $1.49, while resistance sits at $1.77. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.36 (+115.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LXRX is in a strong uptrend. Immediate support is located at $1.49, while resistance sits at $1.77. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $3.36 (+115.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Fair Price Range
$1.52 -
$1.68
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
87.9%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- BULLISH: Trading 115.4% below Wall St target ($3.36)
- CAUTION: Recommendation downgraded due to -9.3% 5-day decline
Fair Price Analysis
30-Day Fair Range
$1.52 -
$1.68
Current vs Fair Value
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$1.49
Resistance Level
$1.77
Current Trend
Strong Uptrend
Technical data as of
Mar 31, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-7.50
Wall Street Target
$3.36
(+115.4%)
Revenue Growth (YoY)
-79.3%
Earnings Growth (YoY)
-63.4%
Profit Margin
-101.1%
Share & Embed Analysis
Last updated: April 01, 2026 1:57 AM ET
Data refreshes hourly during market hours. Next update: 2:57 AM
Data refreshes hourly during market hours. Next update: 2:57 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXRX showing a specific setup today?
Insider Activity (6 Months)
5
Buys
0
Sells
+
Net
INSIDERS BUYING
Recent Transactions
Raymond Debbane
BUY
2000 shares
2026-02-25
Raymond Debbane
BUY
100000 shares
2026-02-23
Raymond Debbane
BUY
100000 shares
2026-02-20
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$25 | 55 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$213 | 66 BUY |
|
IMVT
Immunovant Inc |
STRONG BUY
14 analysts |
$40 | 60 HOLD |
|
CNTA
Centessa Pharmaceuticals… |
STRONG BUY
11 analysts |
$40 | 63 BUY |
|
GPCR
Structure Therapeutics I… |
STRONG BUY
14 analysts |
$109 | 47 HOLD |